RxDoctor Payments Data

Nathan Frank

Optometrist · Anchorage, AKNPI 1588812390

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (57.7%), food and beverage and education — rather than concentrated in one kind of arrangement. 15 manufacturers reported payments, led by Johnson & Johnson Vision Care, Inc. at 57.7% of the total. Reporting peaked in 2022 at $2,274 and has fallen 94.0% since, to $137 in 2024. Among optometrist clinicians in AK with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,509in general payments, 2019–2025

Across 53 payments — averaging $66.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson Vision Care, Inc.$2K
  • Alcon$304
  • Sun Pharmaceutical Industries Inc.$249
  • AbbVie$195
  • Novartis$146
  • Sight Sciences, Inc.$103
  • plus $488 from 9 others

What the payments were for

  • Consulting fees$2,02558%
  • Food & beverage$1,46642%
  • Education$181%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,509 in reported general payments places this provider in the 90th percentile of 163 optometrist providers in Alaska.

See all optometrist providers in Alaska

Medicare billing

Part B allowed, 2024
$31,439
Medicare patients
118
Services billed
432

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast15$24,713
TyrvayaVarenicline Tartrate12$7,616
Loteprednol Etabonate20$3,947
Latanoprost13$382

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra$95$24,71315 claims
Oyster Point Pharma, Inc.Tyrvaya$66$7,61612 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$75$3,94720 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 163 optometrist providers in Alaska.

Other optometrist in Anchorage

See the full list for Alaska

Where these figures come from

Is this you, or does something look wrong? →